Rigel Pharmaceuticals | RIGL - Assets


Rigel Pharmaceuticals reported $242.53M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agenus USD 186.46M 40.34M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Celldex Therapeutics USD 511.25M 71.73M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Veracyte USD 1.44B 30.38M Mar/2026